1-4 of 4
Peter Croucher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract IA015: Niche-dependent control of tumor cell dormancy

Peter Croucher, Weng Hua Khoo, Ryan Chai, Alex Corr, James Smith, Qihao Ren, Paul Baldock, Michelle McDonald, Sheila Stewart, Tri G. Phan
Journal: Cancer Research
Cancer Res (2021) 81 (5_Supplement): IA015.
https://doi.org/10.1158/1538-7445.TME21-IA015
Published: 01 March 2021
View article titled, Abstract IA015: Niche-dependent control of tumor cell dormancy
Journal Articles

Abstract 1885: Selective Polo-like Kinase 1 (PLK1) inhibitor PCM-075 is highly active alone and shows synergy when combined with FLT3 inhibitors in models of acute myeloid leukemia (AML)

Karena Kosco, Maya Ridinger, Penn Whitley, Peter Croucher, Jeffrey N. Miner, Mark Erlander
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1885.
https://doi.org/10.1158/1538-7445.AM2018-1885
Published: 01 July 2018
View article titled, Abstract 1885: Selective Polo-like Kinase 1 (PLK1) inhibitor PCM-075 is highly active alone and shows synergy when combined with FLT3 inhibitors in models of acute myeloid leukemia (AML)
Journal Articles

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma

Sarah Deleu, Miguel Lemaire, Janine Arts, Eline Menu, Els Van Valckenborgh, Isabelle Vande Broek, Hendrik De Raeve, Les Coulton, Ben Van Camp, Peter Croucher, Karin Vanderkerken
Journal: Cancer Research
Cancer Res (2009) 69 (13): 5307–5311.
https://doi.org/10.1158/0008-5472.CAN-08-4472
Published: 01 July 2009
View article titled, Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
Open the PDF for Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma in another window
Journal Articles

Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma

Karin Vanderkerken, Evy De Leenheer, Claire Shipman, Kewal Asosingh, Angelo Willems, Ben Van Camp, Peter Croucher
Journal: Cancer Research
Cancer Res (2003) 63 (2): 287–289.
Published: 15 January 2003
View article titled, Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma
Open the PDF for Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma in another window